Victoza gained FDA approval in 2010, for the treatment of Type 2 diabetes, yet only a short time later, adverse reports began coming in to the FDA. Victoza is manufactured by a Danish company, Novo Nordisk; the company was required to conduct a five-year study to determine the risks of pancreatitis, hypoglycemia, serious allergic reactions, pancreatic cancer and thyroid cancer among Victoza patients. Victoza was also approved with the understanding that it would be a second-line defense drug which means it would only be prescribed when other drug treatment was unsuccessful. 

Many of those who have taken the Type 2 diabetic drug, Victoza, may be wondering whether they are entitled to file a Victoza lawsuit to recover expenses related to adverse health symptoms developed after starting the drug. Victoza, manufactured by Novo Nordisk, gained FDA approval in 2010, although there were two FDA pharmacologists and one FDA Clinical Safety Reviewer who were opposed to approving the drug until further studies had been done. This March, a Drug Safety Communication was sent out to alert the public to a potential risk of Victoza in the development of pancreatitis, pancreatic cancer and thyroid cancer.

For all those who have been harmed from taking a drug which was not well-tested or simply turned out to be dangerous, their only recourse may be to file a lawsuit against the manufacturer of the drug in order to obtain compensation for their injuries. Byetta is one such drug; research has shown that Byetta may bring potential risks of serious illness among those taking the drug. Byetta was developed to treat Type 2 diabetes, along with diet and exercise by controlling blood sugar in the body when it becomes too high.

Byetta, a drug approved for the treatment of Type 2 diabetes may carry significant risks for diseases such as thyroid cancer, pancreatitis and pancreatic cancer. Byetta, a synthesized version of a hormone found in the saliva of the Southwestern Gila lizard, is taken by the patient via an injection twice daily prior to breakfast and dinner. The active ingredient in Byetta is exenatide and is in a class of drugs known as incretin mimetcs. Exenatide imitates the actions of incretin which is normally produced by the intestines to suppress the release of glucose from the liver.

Recent reports in the JAMA Internal Medicine indicate that patients taking Januvia are at a higher risk of developing pancreatitis when compared with those taking other Type 2 diabetic drugs which do not contain sitaglipin. The JAMA journal found that those suffering from pancreatitis who were hospitalized were twice as likely to have been taking Januvia.  Januvia is an oral anti-hyperglycemic belonging to a class of drugs known as incretin mimetics which stimulate the production of insulin.